On Friday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $17.07. Advaxis, Inc. (NASDAQ:ADXS) on April 30, 2015, reported the pricing of its previously announced underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock from Advaxis.
CytRx Corporation (NASDAQ:CYTR) in last trading activity moved down -15.72% to close at $3.70. Company weekly performance is -27.88% while its quarterly performance stands at 43.97%. CytRx Corporation (NASDAQ:CYTR) is -32.23% away from its 52 week high. CytRx Corp. (NASDAQ:CYTR) on Friday reported a loss of $17.5 million in its first quarter. The Los Angeles-based company said it had a loss of 31 cents per share. Losses, adjusted for non-recurring costs, came to 28 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share. The company’s shares closed at $4.39. A year ago, they were trading at $3.07.
On last trading day General Electric Company (NYSE:GE) advanced 0.85% to close at $27.31. Its volatility for the week is 1.32% while volatility for the month is 1.88%. GE’s sales growth for past 5 years was -0.80% and its EPS growth for past 5 years was 8.80%. On 22 April, General Electric Company (NYSE:GE) monthly performance is 9.94%. General Electric Co. (NYSE:GE) Unit (GE), GE Energy Financial Services has entered into a partnership with Green Power Investment Corp. for investment in a 42-megawatt (DC) photovoltaic solar power project in Futtsu City, Japan.
Ply Gem Holdings, Inc (NYSE:PGEM) has 0.40% insider ownership while its institutional ownership stands at 41.70%. In last trading activity company’s stock closed at $13.84. Ply Gem Holdings (NASDAQ:PGEM) was downgraded by Zacks from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.
On last trading day Vical Incorporated (NASDAQ:VICL) moved down -3.16% to close at $0.92. Its volatility for the week is 6.31% while volatility for the month is 4.62%. VICL’s sales growth for past 5 years was 3.70% and its EPS growth for past 5 years was 20.80%. Vical Incorporated (NASDAQ:VICL) monthly performance is -2.13%. Vical Incorporated (NASDAQ:VICL) is presenting the latest data from its pre-clinical studies on combining Vaxfection-formulated glycoprotein-B (gB)-encoding DNA vaccines in eliminating antibody responses at the fifth International Congenital CMV Conference in Brisbane, Australia. “A vaccine to prevent birth defects caused by cytomegalovirus is a public health priority,” Virginia Commonwealth University Emeritus Professor in the Department of Microbiology and Immunology Stuart Adler said on 22 April.